Quintrio
Home

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Tarsus Pharmaceuticals, Inc. Common Stock

TARS

Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.

Last trade $77.87
Day change -$0.81 (-1.03%)
Day range $76.31 – $78.72
Volume 212,311
Market cap $3.88B

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$3.88B
Price / earnings
—
Price / book
37.29×
Price / sales
5.69×
EV / sales
5.59×
EV / EBITDA
-5.46×

Profitability

Earnings per share
-$14.25
Return on assets
-139.01%
Return on equity
-675.49%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0.7×
Current ratio
1.96×
Quick ratio
1.94×
Cash ratio
0.6×

Cash flow

Price / cash flow
77.74×
Price / free cash flow
119.58×
Free cash flow
$32.44M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for TARS, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$194.57M$173.91M$162.05M$151.67M$118.7M$102.66M$78.34M$66.41M
Cost of revenue$13.89M$12.11M$9.4M$10.93M$8.31M$6.24M$5.21M$4.93M
Gross profit$180.68M$161.8M$152.66M$140.74M$110.39M$96.42M$73.12M$61.48M
Selling, general and administrative$168.02M$150.7M$136.43M$130.68M$108.63M$103.01M$85M$69.03M
Research and development$676.37M$31.01M$22.35M$18.04M$16.28M$15.59M$14.41M$16.87M
Total operating expenses$842.77M$181.71M$158.78M$148.72M$124.92M$118.61M$99.4M$85.9M
Operating income-$662.09M-$19.91M-$6.12M-$7.98M-$14.53M-$22.18M-$26.28M-$24.42M
Interest expense-$2.19M-$2.16M-$2.13M-$2.21M-$2.27M-$2.24M-$2.21M-$2.31M
Income before taxes-$663.69M-$15.84M-$4.62M-$6.31M-$12.59M-$20.34M-$25.12M-$23.11M
Income taxes$4.64M$2.72M$2.35M$2.06M$0$0$0$0
Net income-$668.33M-$18.55M-$6.97M-$8.37M-$12.59M-$20.34M-$25.12M-$23.11M
Net income attributable to common shareholders-$668.33M-$18.55M-$7.65M-$8.17M-$12.59M-$20.34M-$25.21M-$22.93M
EBITDA-$661.07M-$18.06M-$6.53M-$13.02M-$14.07M-$20.42M-$27.13M-$28.2M
Basic earnings per share-$14.40-$0.43-$0.16-$0.19-$0.30-$0.48-$0.64-$0.59
Diluted earnings per share-$14.40-$0.43-$0.16-$0.19-$0.30-$0.48-$0.64-$0.59

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

HRMY Q3 Earnings Miss Estimates on Higher Costs Despite Wakix Growth

Harmony Biosciences reported Q3 EPS of 81 cents, missing consensus estimates of $1.00, despite 12% revenue growth to $269 million. Higher R&D spending, a $25 million MSN milestone charge, and royalty expenses pressured profitability. The company reaffirmed its 2026 Wakix revenue guidance of $1-$1.04 billion, supported by sustained patient demand and 400 net patient additions. The pipeline includes promising Phase I results for BP-205 and ongoing late-stage studies for pitolisant formulations and epilepsy programs.

Zacks Investment Research

Tarsus Pharmaceuticals, Inc. (TARS) Reports Q3 Loss, Tops Revenue Estimates

Tarsus Pharmaceuticals reported a Q3 loss of $0.78 per share, beating consensus estimates of $1.43 loss by 45.46%. Revenue reached $194.57 million, surpassing estimates by 3.06% and up 64% year-over-year. The company has topped revenue estimates four times in the last four quarters and holds a Zacks Rank #2 (Buy) rating, though shares have underperformed the S&P 500 by 20.7% year-to-date.

Zacks Investment Research

How Much Upside is Left in Tarsus Pharmaceuticals (TARS)? Wall Street Analysts Think 30.78%

Tarsus Pharmaceuticals (TARS) has gained 2.5% over the past four weeks and closed at $74.85. Wall Street analysts project a mean price target of $97.89, indicating potential upside of 30.8%. The stock holds a Zacks Rank #2 (Buy) rating, supported by positive earnings estimate revisions with the consensus estimate increasing 3.1% over the past month. However, the article cautions that price targets alone should not be the sole basis for investment decisions.

Zacks Investment Research

Harmony Biosciences Holdings, Inc. (HRMY) Reports Next Week: Wall Street Expects Earnings Growth

Harmony Biosciences is expected to report Q3 2026 earnings on November 4, with Wall Street anticipating 14.9% YoY EPS growth to $1.00 per share and 13.1% revenue growth to $270.87 million. However, a negative Earnings ESP of -12.00% combined with recent downward estimate revisions suggests the stock may not beat consensus expectations, despite carrying a Zacks Rank #1 rating.

Zacks Investment Research

Earnings Preview: Tarsus Pharmaceuticals, Inc. (TARS) Q3 Earnings Expected to Decline

Tarsus Pharmaceuticals is expected to report a quarterly loss of $1.43 per share (down 376.7% YoY) with revenues of $188.8 million (up 59.1% YoY) for Q3 2026. The company has a negative Earnings ESP of -40.31% combined with a Zacks Rank #2, making it unlikely to beat consensus estimates. The company has a mixed earnings surprise history, beating estimates in 2 of the last 4 quarters.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.